Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07449702

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Led by Oruka Therapeutics, Inc. · Updated on 2026-04-22

80

Participants Needed

17

Research Sites

149 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

CONDITIONS

Official Title

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent from participants who completed the previous trial and chose to enter this extension study
  • Successfully completed the preceding trial
  • Women of childbearing potential must have a negative urine pregnancy test at baseline
  • Women of childbearing potential and fertile male participants with partners of childbearing potential must agree to use highly effective contraception
Not Eligible

You will not qualify if you...

  • Experienced adverse events with ORKA-001 in the previous trial that prevent continued treatment
  • Developed guttate, erythrodermic, pustular, or drug-induced psoriasis during the previous trial
  • Have any significant disease or medical condition other than psoriasis that could affect safety or data quality
  • Have clinically significant lab abnormalities from the previous trial that prevent continued treatment
  • Are pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Oruka Therapeutics Investigative Site

Los Angeles, California, United States, 90045

Actively Recruiting

2

Oruka Therapeutics Investigative Site

San Diego, California, United States, 92123

Actively Recruiting

3

Oruka Therapeutics Investigative Site

Santa Ana, California, United States, 92701

Actively Recruiting

4

Oruka Therapeutics Investigative Site

Santa Monica, California, United States, 90404

Actively Recruiting

5

Oruka Therapeutics Investigative Site

Cromwell, Connecticut, United States, 06416

Actively Recruiting

6

Oruka Therapeutics Investigative Site

Coral Gables, Florida, United States, 33134

Actively Recruiting

7

Oruka Therapeutics Investigative Site

Bowling Green, Kentucky, United States, 42104

Actively Recruiting

8

Oruka Therapeutics Investigative Site

Rockville, Maryland, United States, 20850

Actively Recruiting

9

Oruka Therapeutics Investigative Site

Detroit, Michigan, United States, 48202

Actively Recruiting

10

Oruka Therapeutics Investigative Site

New York, New York, United States, 10023

Actively Recruiting

11

Oruka Therapeutics Investigative Site

New York, New York, United States, 10029

Actively Recruiting

12

Oruka Therapeutics Investigative Site

Portland, Oregon, United States, 97201

Actively Recruiting

13

Oruka Therapeutics Investigative Site

Surrey, British Columbia, Canada, V3R 6A7

Actively Recruiting

14

Oruka Therapeutics Investigative Site

London, Ontario, Canada, N6H 5L5

Actively Recruiting

15

Oruka Therapeutics Investigative Site

Markham, Ontario, Canada, L3P 1X3

Actively Recruiting

16

Oruka Therapeutics Investigative Site

Peterborough, Ontario, Canada, K9J 5K2

Actively Recruiting

17

Oruka Therapeutics Investigative Site

Toronto, Ontario, Canada, M4W 2N4

Actively Recruiting

Loading map...

Research Team

O

Oruka Clinical Trials Information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | DecenTrialz